Utilizing Topical Sodium Hypochlorite to Ameliorate Radiation Dermatitis

NCT ID: NCT04630821

Last Updated: 2022-08-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-08
• Study Completion Date: 2022-04-25

Brief Summary

The objective of the pilot study is to determine compliance, acceptability, and feasibility of using topical sodium hypochlorite to ameliorate or reduce radiation dermatitis, and to collect preliminary data and estimates for planning a larger efficacy study.

This 3-week single-arm pilot study will collect information on subject treatment compliance and feedback from subjects (and nurses/subject's treating oncologist) on the acceptability of the use of the treatment. We will also collect data on Common Terminology Criteria for Adverse Events and patient reported outcomes measured using the pain and pruritus PROMIS short-form tools and patient reported outcomes, measured using the Dermatology Life Quality Index (DLQI) tool.

Conditions

Radiation Dermatitis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Treatment with Dilute Sodium Hypochlorite solution

Subjects will be treated with the dilute bleach compresses daily (Monday through Friday) for the first 3 weeks of therapy. The bleach solution will be prepared and compresses applied for a 20 minute duration prior to radiation therapy. The compress can be applied within an hour of radiation therapy. Subjects will apply Aquaphor® ointment twice a day, once immediately after the radiation treatment and once in the evening. On days the experimental subjects do not receive radiation therapy, they will continue to moisturize their skin twice a day (AM and PM) with Aquaphor® ointment.

Group Type: EXPERIMENTAL

Dilute Sodium Hypochlorite solution

Intervention Type: OTHER

Subjects will be treated with the dilute bleach compresses daily for the first 3 weeks of therapy.

While these subjects are undergoing radiation therapy, they will be assessed weekly before the day's compress treatment by a physician investigator on the study team. Subjects will be evaluated and photographs will also be taken at study visits 1-3. The subjects will also complete a subject questionnaire addressing patient-reported outcomes at baseline and each weekly check-in during these two weeks. They will be also interviewed about ease of use and treatment tolerability. Subjects will complete interview questions at the end of the study to determine if they would continue the treatment and any obstacles or barriers.

Interventions

Dilute Sodium Hypochlorite solution

Subjects will be treated with the dilute bleach compresses daily for the first 3 weeks of therapy.

While these subjects are undergoing radiation therapy, they will be assessed weekly before the day's compress treatment by a physician investigator on the study team. Subjects will be evaluated and photographs will also be taken at study visits 1-3. The subjects will also complete a subject questionnaire addressing patient-reported outcomes at baseline and each weekly check-in during these two weeks. They will be also interviewed about ease of use and treatment tolerability. Subjects will complete interview questions at the end of the study to determine if they would continue the treatment and any obstacles or barriers.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• 18 years of age or older
• Been diagnosed with head and neck cancer requiring radiation therapy or skin cancer requiring radiation treatment to the neck
• Are scheduled for a radiation therapy planning session (CT simulation)
• Have a scheduled radiation therapy start date within 1 to 2 weeks from the CT simulation
• Are able to comply with the study protocol

Exclusion Criteria

• Patients who are pregnant, which may lead to discontinuation of radiation therapy
• Patients currently on immunotherapy
• Active or past history of inflammatory lesions in the radiation field that could interfere with assessment
• Patients who are undergoing re-irradiation to the head and neck
• Patients must not have any other condition or situation beyond those listed above which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the patient's participation in the study.
• Patients who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function are not eligible.
• Participation in other clinical trials that would alter the radiation dose typically utilized for definitive chemo and radiation therapy treatment of head and neck cancer.
• Use of other topical treatments on the skin in the treatment field. No other products are allowed except Aquaphor® ointment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Northwestern University

OTHER

Sponsor Role: lead

Responsible Party

Amy Paller

Chair, Department of Dermatology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Amy Paller, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Dermatology, Chair

Locations

Northwestern University

Chicago, Illinois, United States

Countries

United States

Other Identifiers

AP09042019

Identifier Type: -

Identifier Source: org_study_id